AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06463548
Drug: irinotecan hydrochloride liposome injection
RxNorm normalized name: irinotecan hydrochloride liposome Injection
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan hydrochloride liposome injection (70mg/m2) will be administered by intravenous infusion on day 1 in a 2-week treatment cycle.
Trial: NCT06463548
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib (8 mg) will be administered orally in a 2-week treatment cycle, once a day from day 1 to day 14 of each cycle
Trial: NCT04685070
Drug: HS-10296 (Almonertinib)
RxNorm normalized name: HS-CoM
DrugBank: Almonertinib (DB16640)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant treatment stage: HS-10296 110mg, qd, po, 4 weeks per cycle, 2-4 cycles in total; Surgical treatment stage: CR + PR patients and SD + PD patients who could still undergo surgery will receive radical surgery; Adjuvant treatment stage: CR, PR and SD patients who have been treated surgically: HS-10296 110mg, qd, po, up to 48 weeks (including neoadjuvant stage). PD patients: transferred into medical oncology or/and radiation oncology and receive comprehensive therapy.
Trial: NCT06371014
Drug: Ondansetron oral membrane
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A new oral film formulation of ondansetron was used to replace traditional tablets in the treatment of antiemetic chemotherapy
Trial: NCT04941755
Drug: BMS-986256
RxNorm normalized name: BMS-986256
DrugBank: Afimetoran (DB16580)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT04941755
Drug: Famotidine
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05851508
Drug: Methylprednisolon
RxNorm normalized name: Methylprednisolon
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intratympanal injection with Methylprednisolon 62.5 mg/ ml
Trial: NCT06736496
Drug: Nalbuphine
RxNorm normalized name: Nalbuphine
DrugBank: Nalbuphine (DB00844)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will receive : nalbuphine administered at a dose of 0.2 mg / kg IV bolus dose before induction and intermittent doses of 0.5 mg/kg if MAP and HR greater than 20% of the base line value.
Trial: NCT06736496
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients will receive : Dexmedetomidine infusion at rate of 0.5mcg/kg/h initiated 10 min before induction and ketamine iv bolus dose of 0.35 mg/kg and Lidocaine iv bolus dose of 1mg/kg administrated before skin incision.
Trial: NCT06735508
Drug: mRNA Neoantigen Vaccine
RxNorm normalized name: ChulaCov19 mRNA vaccine
DrugBank: ChulaCov19 mRNA vaccine (DB16445)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA Neoantigen Vaccine
Trial: NCT06735508
Drug: Adebrelimab
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adebrelimab is a programmed death-ligand 1 antibody.
Trial: NCT04875338
Drug: plate-rich plasma
RxNorm normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1ml prp (plate-rich plasma to be prepared with the blood taken from the patient on the day of injection), , while the patient is in the supine position, the affected elbow is 90 flexion and neutral rotation, The non-dominant thumb will be placed at the sensitive point in the lateral epicondyle. The injection will be applied to the point with a 23 g needle. After the injection, the subjects will be taught a stretching exercise of the joint extensors of the wrist and fingers. Subjects will be asked to do this exercise five times in one session, two sessions a day
Trial: NCT04875338
Drug: saline (0.9 NACI)
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 ml saline (0.9 NACI) while the patient is in the supine position, the affected elbow is 90 flexion and neutral rotation, The non-dominant thumb will be placed at the sensitive point in the lateral epicondyle. The injection will be applied to the point with a 23 g needle. After the injection, the subjects will be taught a stretching exercise of the joint extensors of the wrist and fingers. Subjects will be asked to do this exercise five times in one session, two sessions a day
Trial: NCT04875338
Drug: betametazon
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 ml betametazon while the patient is in the supine position, the affected elbow is 90 flexion and neutral rotation, The non-dominant thumb will be placed at the sensitive point in the lateral epicondyle. The injection will be applied to the point with a 23 g needle. After the injection, the subjects will be taught a stretching exercise of the joint extensors of the wrist and fingers. Subjects will be asked to do this exercise five times in one session, two sessions a day
Trial: NCT05143762
Drug: paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will receive intravenous paracetamol 30mg/kg (max 90 mg/kg/day)
Trial: NCT05143762
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients will receive dexamethasone 0.5mg/kg IV.
Trial: NCT00001048
Drug: Filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00001048
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00001048
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001048
Drug: Zalcitabine
RxNorm normalized name: Zalcitabine
DrugBank: Zalcitabine (DB00943)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001048
Drug: Didanosine
RxNorm normalized name: Didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05818735
Drug: Escitalopram 10mg
RxNorm normalized name: Escitalopram 10mg Oral tablet
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escitalopram will be used as the antidepressants for relieving patients' depressive mood. The dose of the drug will be the minimum clinical starting dose of 10 mg once daily, taken orally in the morning, for a period of 3 months. During the intervention period, patients will be allowed to increase the drug dose (up to 20 mg) according to their mental status. Patients will record the details of the drug dose, duration of dosing,responses and possible side effects on a drug dairy. Pateints will receive 7 tablets of escitalopram from an independent dispencer at a set time each week. They may receive additional dose of escitalopram once again during the week if necessary and it will be recorded by the dispenser.
Trial: NCT05931744
Drug: Budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: after application of topical vasoconstrictor packs into both nasal cavities, using 1 cc 28 gauge needle sterile syringe, one pack of budesonide ampule 0.5 mg/2ml was injected into visible polyps on both cavities 1 ml in each cavity weekly for 5 consecutive weeks
Trial: NCT05931744
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients given oral prednisone 1 mg/ kg with max. dose 70 mg/d divided into two doses for 3 days then tapered gradually for two weeks
Trial: NCT05931744
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: saline intrapolyp injection
Trial: NCT05094323
Drug: Ultrasound-guided deep serratus anterior plane block with isobaric bupivacaine
RxNorm normalized name: Fucus serratus extract
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive ultrasound-guided deep serratus anterior plane block with isobaric bupivacaine.
Trial: NCT05094323
Drug: Local wound infiltration with isobaric bupivacaine
RxNorm normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive local wound infiltration with isobaric bupivacaine.
Trial: NCT05094323
Drug: Ultrasound-guided thoracic paravertebral block with isobaric bupivacaine
RxNorm normalized name: Ivy Block
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive ultrasound-guided thoracic paravertebral block with isobaric bupivacaine.
Trial: NCT06636552
Drug: Daratumumab (Subcutaneously)
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: D-PAD (21-Day Cycles 1, 3 and 5):~1,800 mg (QW) SC on days 1, 8, and 15 (for Cycles 1 and 3) 1,800 mg (Q3W) SC on day 1 (for Cycle 5)~D-CVD (21-Day Cycles 2, 4, 6, 7 and 8):~1,800 mg (QW) SC on days 1, 8, and 15 (for Cycle 2) 1,800 mg (Q3W) SC on day 1 (for Cycles 4, 6, 7 and 8)~Daratumumab monotherapy (28-Day Cycles 9 to 32):~1,800 mg (Q4W) SC on day 1
Trial: NCT05787418
Drug: HH-120 Nasal Spray
RxNorm normalized name: HH-009
DrugBank: HH-009 (DB18727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HH-120 nasal spray 8 times per day for 7 consecutive days
Trial: NCT05369052
Drug: Linezolid (IV and PO)
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Linezolid (IV and PO) administered for a total of 14 to 28 days (28 to 56 doses)
Trial: NCT05542355
Drug: EXL01
RxNorm normalized name: Elexacaftor
DrugBank: Elexacaftor (DB15444)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral EXL01 once daily for up to 24 weeks (after SoC corticosteroid induction therapy).
Trial: NCT06543979
Drug: lubiprostone , single arm
DrugBank: Lubiprostone (DB01046)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: laxative
Trial: NCT04723875
Drug: Paclitaxel or docetaxel + Cisplatin or carboplatin
RxNorm normalized name: Medicated Pad or Tape
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paclitaxel 135-175mg/m2 over 3 hours or docetaxel 70-75 mg/m2， 30min ＋ Cisplatin 75-80mg/m2 or carboplatin AUC = 5, repeat per 21 days.
Trial: NCT04639414
Drug: Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Measurement of the effect of the combined treatment with semaglutide 1mg/week and empagliflozin 10 mg/d compared to matching placebo after 48-week treatment.
Trial: NCT04639414
Drug: Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide
RxNorm normalized name: semaglutide Pen Injector
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Measurement of the effect of empagliflozin monotherapy 10mg/d compared to matching placebo after 48-week treatment.
Trial: NCT04639414
Drug: Placebo matching empagliflozin and placebo pen injector matching semaglutide
RxNorm normalized name: semaglutide Pen Injector
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Measurement of the effect of the combined treatment with semaglutide 1mg/week and empagliflozin 10 mg/d OR empagliflozin monotherapy 10mg/d compared to matching placebo after 48-week treatment.
Trial: NCT06498752
Drug: PD-1 monoclonal antibody consolidation therapy
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 monoclonal antibody-based consolidation therapy for 1 year after completion of radiotherapy (or combination chemotherapy up to 4 cycles if less than 4 cycles of chemotherapy). Specific dosing: PD-1 monoclonal antibody, 200mg every 3 weeks.
Trial: NCT04452461
Drug: Gemcitabine / Nab-paclitaxel
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Both drugs are administered once weekly for three weeks (days 1, 8, 15) followed by a week of rest (28-day cycle) for 3 cycles prior to imaging. Gemcitabine: 1000 mg/m2 intravenous infusion over 30 to 40 minutes. Nab-paclitaxel: 125 mg/m2 intravenous infusion over 30 to 40 minutes.
Trial: NCT05996003
Drug: NS-089/NCNP-02
DrugBank: Brogidirsen (DB18884)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1:~Part 1 Dose Level 1-3: a 4-week Treatment Phase at each treatment dose level~Part 2 Single Dose Level: a 24-week Treatment Phase at the MTD of Part 1~Cohort 2:~Part 2 Single Dose Level: a 24-week Treatment Phase at the MTD of Part 1
Trial: NCT05994235
Drug: Mosunetuzumab
RxNorm normalized name: Mosunetuzumab
DrugBank: Mosunetuzumab (DB15434)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosunetuzumab will be administered in weekly dose increments (step-up dosing) during Cycle 1 and then on Day 1 of each cycle. Mosunetuzumab will be given in 28-day cycles for up to 12 cycles. Mosunetuzumab will be administered SC at the dose of 5 mg on Day 1, 45 mg on Day 8, and 45 mg on Day 15 in Cycle 1. Beginning with Cycle 2, it will be administered SC at the dose of 45 mg on Day 1. Each cycle lasts 4 weeks.
Trial: NCT05994235
Drug: Tazemetostat Pill
RxNorm normalized name: tazemetostat Pill
DrugBank: Tazemetostat (DB12887)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral tazemetostat will be administered by mouth twice daily at standard dosing (800 mg twice daily) beginning at the same time as mosunetuzumab initiation until disease progression, unacceptable toxicity, or consent is withdrawn. Patients will remain on tazemetostat for up to twelve 28-day cycles from initiation of mosunetuzumab.
Trial: NCT06635317
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg/day orally for 25 days
Trial: NCT06635317
Drug: enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/day subcutaneously for 28 days, with the dose reduced to 20 mg for patients weighing less than 50 kg or with an estimated glomerular filtration rate less than 30 mL/min/1.73 m².
Trial: NCT06577532
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-1 antibody, administered intravenously
Trial: NCT04740294
Drug: Magnesium Sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Randomized to receive either magnesium sulfate or normal saline placebo.
Trial: NCT06186648
Drug: Glofitamab + Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Duration of each cycle is 21 days. Cycle 1: R-CHOP Cycle 2: G-CHOP + glofitamab (at this cycle onnly, Obinutuzumab will be injected instead of Rituximab in order to decreased the risk of cytokine released syndrome) Cycle 3-6: R-CHOP + glofitamab Cycle 7-8: glofitamab alone
Trial: NCT04968938
Drug: midomafetamine
RxNorm normalized name: Midomafetamine
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg or 120 mg midomafetamine HCl followed by a 40 mg supplement dose
Trial: NCT06393881
Drug: UI059
RxNorm normalized name: Ulimorelin
DrugBank: Ulimorelin (DB12128)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: take UI059 once a day for 7 days
Trial: NCT05441930
Drug: Levofloxacin Ocular Implant
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin Ocular Implant an implant that delivers a bolus dose of levofloxacin and a constant daily dose for a further 5-7 days.
Trial: NCT05441930
Drug: Control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available topical medications as per LEVO-CS102 Surgical Therapy Procedure.
Trial: NCT04247750
Drug: Sirolimus 0.5 mg
RxNorm normalized name: sirolimus 0.5 MG
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daily administration of 1 or more tablets
Trial: NCT05564286
Drug: Fosaprepitant
RxNorm normalized name: Fosaprepitant
DrugBank: Fosaprepitant (DB06717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In fosaprepitant group, patients would receive fosaprepitant combined with tropisetron plus dexamethasone to prevent chemoradiotherapy-induced nausea and vomitting while the control group would only be given tropisetron and dexamethasone .
Trial: NCT05564286
Drug: tropisetron
RxNorm normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients received tropisetron 5mg on day 1.
Trial: NCT05564286
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: .All patients received dexamethasone 5mg infusion on day 1 and oral dexamethasone 3.75 mg once a day on day 2-3.
Trial: NCT04798391
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Steroids and analgesics
Trial: NCT05477797
Drug: Ixazomib DX/Lenalidomide DX
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: After assessment of risk stratification，patients will be assigned to Id or Rd group randomly for maintenance therapy. Then they will be reviewed the efficacy monthly.
Trial: NCT05321251
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: see arm description
Trial: NCT05713318
Drug: HH-120 nasal spray
RxNorm normalized name: HH-009
DrugBank: HH-009 (DB18727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal spray daily doses of HH-120 4 times added on SOC for 6 consecutive days.
Trial: NCT05713318
Drug: HH-120 nasal spray
RxNorm normalized name: HH-009
DrugBank: HH-009 (DB18727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal spray daily doses of HH-120 8 times added on SOC for 6 consecutive days.
Trial: NCT05688579
Drug: Mineralocorticoid Receptor Antagonists(MRAs)
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will be treated with mineralocorticoid receptor antagonists(MRAs) in addition to the original antihypertensive drugs for 48 months.
Trial: NCT05596968
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
Trial: NCT05505838
Drug: Patisiran
RxNorm normalized name: patisiran
DrugBank: Patisiran (DB14582)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patisiran administered by intravenous (IV) infusion
Trial: NCT04764396
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FNB will be performed as current standard methods in the medical procedure unit without the use of heparin priming. Pass 1, 2, and 3 will be collected in separate jars and sent to pathology, as per standard clinical procedures. Between passes, after tissue is extracted from the needle, the needle will be flushed saline and or air as per current standards of care.
Trial: NCT05008679
Drug: Oseltamivir
RxNorm normalized name: Oseltamivir
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: at a dose of 75 mg twice daily
Trial: NCT04788108
Drug: Dydrogesterone
RxNorm normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dydrogesterone tablet
Trial: NCT03972124
Drug: CBD 100 mg OD
RxNorm normalized name: CBD
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: CBD oil - purified to \<1% THC in soft-gel capsules
Trial: NCT03972124
Drug: CBD 200 mg OD
RxNorm normalized name: CBD
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: CBD oil - purified to \<1% THC in soft-gel capsules
Trial: NCT00002218
Drug: CI-1012
RxNorm normalized name: CI 77266
DrugBank: Carbon black (DB11980)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06433180
Drug: Administration of fecal microbiota transplantation ( FMT capsules)
DrugBank: Fecal microbiota (DB17743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, capsulized, frozen fecal microbiota transplantation FMT delivering approximatively 24 g of stools taken in one day in two separate meals. Administration of the FMT after colon cleaning.
Trial: NCT05328921
Drug: Antihistaminics
RxNorm normalized name: Ahist Antihistamine
DrugBank: Histamine (DB05381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with narrow angle glaucoma and on systemic antihistaminic drugs.
Trial: NCT06669078
Drug: Nal-lRl+Oxaliplain+5- FU +PD 1
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nal-lRl+Oxaliplatin+5- FU +PD-1, these drugs are given on d1, d15, 28 days as one cycle, SBRT is performed during the third and fourth cycle.
Trial: NCT06669078
Drug: Nal-lRl+Oxaliplain+5- FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nal-lRl+Oxaliplatin+5- FU, these drugs are given on d1, d15, 28 days as one cycle.
Trial: NCT06161909
Drug: sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg fixed dose Q3W,1 year
Trial: NCT03762395
Drug: CXA-10
RxNorm normalized name: CXA-10
DrugBank: CXA-10 (DB15026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 weeks of treatment with 150 mg/day of orally administered CXA-10
Trial: NCT04589819
Drug: Teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Teriparatide, an injectable synthetic parathyroid hormone, will be tested to evaluate its efficacy for decreasing the convalescence after a diaphyseal tibial stress fracture, a specific bone stress injury.